Neuberger Berman Investment Advis has recently announced that it has increased stake in Standard BioTools Inc. (NASDAQ:LAB) by 3.59%. After grabbing 4.51 million shares, the institutional investor is now in possession of 0.16 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.70% having worth around $7.66 million. Moreover, Morgan Stanley Investment Managem increased its share by 0.11 million to have a control over 3.11 million shares. And BlackRock Fund Advisors raised its holdings to 11783.0 shares by acquiring 1.39 million shares or 1.76% of the stake.
Standard BioTools Inc. (LAB) concluded trading on 05/25/23 at a closing price of $2.56, with 0.95 million shares of worth about $2.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 93.94% during that period and on Thursday the price saw a gain of about 1.99%. Currently the company’s common shares owned by public are about 79.08M shares, out of which, 77.71M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the LAB stock and their offered price forecasts bring an average price target of $6.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.00 and could fall to a lowest price of $6.00. However, touching the estimated high of $6.00 would mean a gain of 57.33% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 37 times over the past 12 months. They bought 2,170,607 shares in 32 of the transactions. In 5 selling transactions, insiders dumped 2,908,282 shares.
Needham Small Cap Growth Fund, PRIMECAP Odyssey Aggressive Growt, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Standard BioTools Inc. Needham Small Cap Growth Fund is currently holding 3.65 million shares of worth totaling $6.2 million. The company recently came buying 0.0 shares which brought its stake up to 4.61% of the company’s outstanding shares. PRIMECAP Odyssey Aggressive Growt sold -0.12 million shares, after which its hold over company’s outstanding shares shrunk to 4.57%, leaving 3.61 million shares with the mutual fund that have a worth of about $6.14 million. Vanguard Total Stock Market ETF, after buying 2.86 million shares, have now control over 3.61% of the stake in the company. It holds 0.0 shares of worth $4.86 million.
Standard BioTools Inc. (NASDAQ: LAB) started trading at $2.52, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 2.6500, or with a gain of 1.99%. Stock saw a price change of 17.16% in past 5 days and over the past one month there was a price change of 55.15%. Year-to-date (YTD), LAB shares are showing a performance of 118.80% which increased to 31.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.92 but also hit the highest price of $2.61 during that period. The average intraday trading volume for Standard BioTools Inc. shares is 281.56K. The stock is currently trading 37.04% above its 20-day simple moving average (SMA20), while that difference is up 35.62% for SMA50 and it goes to 58.57% higher than SMA200.
Neuberger Berman Investment Advis acquired 4.51 million shares of Standard BioTools Inc. having value of about $7.66 million. Data submitted at the U.S SEC by Neuberger Berman Investment Advis revealed that the firm now holds 0.16 million shares in the company valued at close to $399733.76, or have control over 3.59% stake in the company. Standard BioTools Inc. (NASDAQ: LAB) currently have 79.08M outstanding shares and institutions hold larger chunk of about 71.60% of that. Holding of mutual funds in the company is about 39.88% while other institutional holders and individual stake holders have control over 76.74% and 24.19% of the stake respectively.
The stock has a current market capitalization of $191.49M and its 3Y-monthly beta is at 1.51. It has posted earnings per share of -$1.67 in the same period. It has Quick Ratio of 3.90. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LAB, volatility over the week remained 8.34% while standing at 9.26% over the month.
Analysts are in expectations that Standard BioTools Inc. (LAB) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -210.60%.
Analysts at 1 brokerage firms have issued recommendations for the Standard BioTools Inc. (LAB)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Leave a Reply